Corporate ActionJul 15, 2026, 04:07 PM
AEON Biopharma Closes $12.2M Net Public Offering
AI Summary
AEON Biopharma, Inc. closed its underwritten public offering on July 15, 2026, raising approximately $12.2 million in net proceeds. The offering comprised 17,851,599 shares of Class A common stock and 24,837,008 pre-funded warrants, each accompanied by two-year and five-year milestone warrants. The company plans to utilize the net proceeds for working capital and general corporate purposes, specifically mentioning comparative analytical testing for ABP-450. The offering also provides potential for an additional $29.6 million in gross proceeds upon the cash exercise of the milestone warrants.
Key Highlights
- Net proceeds from the offering totaled approximately $12.2 million.
- Offering included 17,851,599 shares of Class A common stock.
- Offering included 24,837,008 pre-funded warrants.
- Combined public offering price was $0.3221 per share/warrant with milestone warrants.
- Over-allotment option exercised for 6,403,290 two-year and 6,403,290 five-year milestone warrants.
- Potential for an additional $29.6 million in gross proceeds from milestone warrant exercise.
- Proceeds will be used for working capital and general corporate purposes, including ABP-450 testing.
Price Impact
More from AEON